Age Associated Coronavirus Disease 2019 Incubation Period: Impact on Quarantine Policy

Daewoo Pak¹, Klaus Langohr², Jing Ning¹, Jordi Cortés Martínez², Guadalupe Gómez Melis²*, Yu Shen¹,**

Abstract

A unified 14-day quarantine may not effectively contain the spread of COVID-19. With the current recommendation of a uniform 14-day quarantine, up to 9.2% of patients 42 or younger and 18.6% of patients older than 42 years could develop symptoms after the end of the period.

Keywords: Age-specific quarantine policy, COVID-19, Generalized odds-rate class of models, Incubation period, Infectious disease

¹Department of Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
²Department of Statistics and Operations Research, Universitat Politècnica de Catalunya, Barcelona, Spain

*lupe.gomez@upc.edu
**yshen@mdanderson.org

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
1. Introduction

The coronavirus disease 2019 (COVID-19) was first reported in Wuhan, China, in December 2019; an outbreak rapidly spread worldwide. The novel virus infection can be asymptomatic or unapparent during a certain period and asymptomatic persons could spread the virus unknowingly. Among patients who develop symptoms, the incubation period is defined as the elapsed time between infection and appearance of the first symptom. Knowledge of the incubation period is essential for disease prevention, facilitating an optimal quarantine guideline to confine the spread.

The incubation period of COVID-19 was investigated in several reports. Despite its importance, it remains unclear how the incubation distribution could vary by gender and age and whether the current 14-day quarantine period ignoring the patient demographic factors would be sufficient for the containment of COVID-19. A more accurate estimation of the incubation period using these factors can optimize COVID-19 surveillance guidelines. We estimate distribution of the incubation periods of COVID-19, and its association with gender and age, using the best available information to model uncertain dates of infection and symptom onset.

2. Methods

Our analysis was based on publicly reported, clinically confirmed cases with symptoms from two sources, available as of March 30, 2020. To obtain the period of potential exposure, we included the following patients in the analytic dataset: 1) non-residents of Wuhan who visited Wuhan since December 1, 2019 and for whom the exposure period was the time between the earliest possible arrival to and the latest possible departure from Wuhan; 2) people with travel history of visiting the coronavirus-affected nations known at the time or taking a Diamond Princess cruise; 3) non-travel related cases with an exposure history based on contact with infected persons. Among these, 312 cases had recorded exposure periods, or at least an exposure ending date, and dates of symptom onset or hospitalization, as well as gender and age; this number reflects removal of 34 potentially duplicated cases (Supplement S1).

There were 111 cases with complete information on the exposure period (Supplement S2). For cases without an exact starting date of exposure interval, the initial date was set to have a maximum of thirty days of exposure.
or December 1, 2019, whichever one was later. The ending date of exposure was set to precede the known dates of symptom onset and hospitalization. If the exact date of symptom onset was unknown, it was assumed to have occurred before hospitalization (i.e., left-censored).

3. Results

In a total of 312 patients, the median age was 42 (interquartile range 33-55) years and 126 (40.4%) were women. Age was dichotomized at its median prior to the analysis. The effects of gender and age on the incubation period were estimated under the generalized odds-rate class of regression models, which consists of general parametric models including the log-logistic proportional odds models and the Weibull proportional hazards models, as special cases. We estimated the distribution of incubation period by modelling the interval-censored exposure duration and the possible left-censored symptom onset time (Supplement S3). Figure 1 depicts four types of observed patient cases used for modelling.

Patients older than 42 years of age have, on average, longer incubation periods, compared to 42-year-old or younger patients (p=0.036), whereas gender has no effect on the incubation period (p=0.417). The median incubation period is 6.3 (95% CI 5.4-7.2) days overall, being 5.5 (95% CI 4.5-6.5) days and 7.2 (95% CI 5.8-8.6) days for younger and older patients, respectively. The mean incubation period is 6.7 (95% CI 5.5-7.9) days for the younger patients, and 8.7 (95% CI 7.2-10.2) days for the older patients (Supplement S4). Table 1 shows the estimated differences of days between the quantiles of incubation distribution from two age groups. The incubation period difference between the two age groups was not obvious at the 25th quantile or lower; however, it becomes conspicuous after the medians, leading to 6-day differences between the two age groups at the 97.5th quantile.

<table>
<thead>
<tr>
<th>Percentile</th>
<th>2.5th</th>
<th>25th</th>
<th>50th</th>
<th>95th</th>
<th>97.5th</th>
</tr>
</thead>
<tbody>
<tr>
<td>Difference (days, 95% CI)</td>
<td>0.1 (0.0, 0.3)</td>
<td>0.9 (0.0, 1.7)</td>
<td>1.7 (0.1, 3.3)</td>
<td>2.8 (0.1, 5.5)</td>
<td>5.9 (0.3, 11.5)</td>
</tr>
</tbody>
</table>
Patient Cases for Data Analysis

Case I: observing potential exposure period and symptom onset date (235 patients)

Case II: observing potential exposure period and hospitalization date (60 patients)

Case III: observing exact exposure date and symptom onset date (16 patients)

Case IV: observing exact exposure date and hospitalization date only (1 patient)

Figure 1: Four types of observed cases for data analysis (a total of 312 patients)

4. Discussion

The finding that persons older than 42 years have longer incubation periods than those who are younger has important implications for enacting age-specific quarantine policies. This result agrees with previous studies on Severe Acute Respiratory Syndrome that showed a relationship between age
and the incubation period. Using the uniform 14-day quarantine policy recommended by the World Health Organization and the US Centers for Disease Control and Prevention, our estimators imply that 9.2% (95% CI 3.5-14.8%) of COVID-19 patients younger than 42, and 18.6% (95% CI 11.3-25.9%) of older patients may pose a risk of infection to others before onset of their symptoms in the worst-case scenario. Using a 21-day quarantine, these percentages reduced to 1.7% (95% CI 0-3.7%) and 5.6% (95% CI 1.5-9.7%), respectively. To ensure that at least 90% of cases’ symptoms being manifested during quarantine periods, the required durations are estimated to be 14 (95% CI 11-16) days for patients 42 years of age or younger and 18 (95% CI 15-21) days for patients older than 42 years. As such, a unified quarantine policy could be inefficient during a viral outbreak. These estimates were derived from the conservative assumption that the quarantine periods started immediately after infection.

We used a larger data cohort consisting of more confirmed COVID-19 cases than other published papers in this field; the cases may not have the exact symptom onset time (left censored) and include an interval-censored incubation period. Our choice of a parametric model for the incubation period has more flexibility than other commonly used distributions. This flexible model was reduced to the Weibull distribution, a special case as reported in Backer et al[1] and Linton et al[4] (Supplement S5). We also used a descriptive method to check the model fitting by comparing a nonparametric estimation of the incubation distribution for interval-censored data with the model-based estimation under the Weibull distribution by age groups. As shown in Supplement S6, the Weibull distribution fits the data adequately. To examine how sensitive the estimates were to the assumption of 30 days of maximum exposure for cases with missing starting date of exposure interval, we performed the analyses by changing this maximum exposure duration to 20 days or by shifting the lower bound back and forth within 15 days. The changed assumptions had little effect on analysis results (Supplement S7).

This analysis has some notable limitations. Our inferences relied on publicly reported confirmed cases that might over represent more severely symptomatic patients. Moreover, the definition of COVID-19 symptoms and hospitalization criteria could differ by country, especially during the initial outbreak. We combined the data sets from two different sources, and the potential variation in source criteria for tracing infected cases may lead to different exposure records. However, we obtained similar findings when fitting the model to each dataset separately, although one indicated no signif-
icant differences but the same trend in the incubation period between the age groups (Supplement S8). An optimal differentiating cut-off age for the incubation period was not identified here due to the limited available data, which is worth pursuing to reduce risks to public health most effectively.

Acknowledgements

This work was partially supported by the Ministerio de Economía y Competitividad (Spain) [MTM2015-64465-C2-1-R (MINECO/FEDER)] and the Departament d’Economia i Coneixement de la Generalitat de Catalunya (Spain) [2017 SGR 622 (GRBIO)]. All authors report no conflicts of interest relevant to this article.
References


